Please use this identifier to cite or link to this item: http://repo.tma.uz/xmlui/handle/1/5098
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDAMINOV Botir., ABDUVAKHITOVA Asal-
dc.date.accessioned2026-09-05T12:05:16Z-
dc.date.available2026-09-05T12:05:16Z-
dc.date.issued2025-11-06-
dc.identifier.urihttp://repo.tma.uz/xmlui/handle/1/5098-
dc.description.abstractAssociated pulmonary hypertension worsens the prognosis for patients undergoing scheduled hemodialysis. Endothelin receptor antagonists, including bosentan, are standard treatment for pulmonary arterial hypertension. Echocardiography (TTE) remains a key tool for screening and longitudinal monitoring of the right heart and estimating PH probability. In this cohort, the addition of bosentan to comprehensive therapy in maintenance hemodialysis patients with pulmonary hypertension was associated with a marked improvement in pulmonary hemodynamics and right heart function, demonstrating clinical feasibility in carefully selected hemodialysis patients with regular safety monitoring.en_US
dc.language.isoen_USen_US
dc.publisherO'zbekiston (БИОМЕДИЦИНА ВА АМАЛИЁТ ЖУРНАЛИ) N6en_US
dc.relation.ispartofseriesUDC;616.131-073.75:615.33:616.61-085.38-
dc.subjectpulmonary hypertension; chronic kidney disease; hemodialysis; bosentan; echocardiography; TAPSE; sPAP; endothelin-1.en_US
dc.titleDYNAMICS OF ECHOCARDIOGRAPHIC PARAMETERS OF PULMONARY HYPERTENSION DURING BOSENTAN THERAPY IN PATIENTS UNDERGOING PROGRAM HEMODIALYSISen_US
dc.typeArticleen_US
Appears in Collections:

Files in This Item:
File Description SizeFormat 
biomedicine_2025_6сон_GEMODIALIZ_DASTURIDAN_O'TAYOTGAN_BEMORLARDA.pdf975.07 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.